Filing Flows › Treace Medical Concepts (TMCI) › Q2 2026
Treace Medical Concepts (TMCI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Treace Medical Concepts (TMCI) reported revenue of $45.4M for the second quarter 2026 (Q2 2026), -4% from a year earlier and -4% from the quarter before. Operating margin was -33.0%, net loss $15.9M (35.0% of revenue).
Treace Medical Concepts, Q2 2026: revenue $45.4M (-4% year over year), operating margin -33.0%, net loss $15.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.4M | -4% | -4% |
| Operating profit | −$15.0M | — | — |
| Net earnings | −$15.9M | — | — |
| Operating cash flow | −$4.7M | -165% | — |
What changed
Revenue was $45.4M in Q2 2026, down 4% year over year and down 4% from the previous quarter.
Gross margin was 78.5%, down 1.2 points from Q2 2025. Operating costs exceeded revenue by $15.0M, an operating margin of -33.0%. Operating expenses fell 8% while revenue fell 4%. The quarter ended with a net loss of $15.9M, narrower than the previous quarter's $18.0M loss.
Operating cash flow was −$4.7M. Non-cash charges added back $1.9M of depreciation and amortization and $6.5M of share-based compensation. Working capital and other items added $2.8M. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$6.9M.
Questions
What was Treace Medical Concepts' revenue in the second quarter 2026?
Treace Medical Concepts (TMCI) reported revenue of $45.4M for the second quarter 2026 (Q2 2026), -4% from a year earlier and -4% from the quarter before.
Was Treace Medical Concepts profitable in the second quarter 2026?
Operating loss was $15.0M (-33.0% of revenue) and net loss $15.9M.